Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Michael Rothenberg

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Cancer Discovery|August 21, 2014
Brain tumor cells in circulation are enriched for mesenchymal gene expressionJames P Sullivan, Brian V Nahed, Marissa W Madden, et al.
Cancer Research|March 11, 2010
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancersS Michael Rothenberg, Gayatry Mohapatra, Miguel N Rivera, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 9, 2010
Isolation of circulating tumor cells using a microvortex-generating herringbone-chipShannon L Stott, Chia-Hsien Hsu, Dina I Tsukrov, et al.
Nature Medicine|April 26, 2011
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapyJoachim Lupberger, Mirjam B Zeisel, Fei Xiao, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2007
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profilingUltan McDermott, Sreenath V Sharma, Lori Dowell, et al.
Cancer Discovery|June 3, 2023
SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted TherapyAlexander Drilon, Manish R Sharma, Melissa L Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2020
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with CrizotinibEzra Y Rosen, Melissa L Johnson, Sarah E Clifford, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 29, 2020
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven MalignanciesBenjamin J Solomon, Lavinia Tan, Jessica J Lin, et al.
Cancer Discovery|May 1, 2024
A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose EscalationRona Yaeger, Meredith A McKean, Rizwan Haq, et al.
Cancer Discovery|June 5, 2017
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid TumorsAlexander Drilon, Ramamoorthy Nagasubramanian, James F Blake, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Cancer Discovery|August 21, 2014
Brain tumor cells in circulation are enriched for mesenchymal gene expressionJames P Sullivan, Brian V Nahed, Marissa W Madden, et al.
Cancer Research|March 11, 2010
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancersS Michael Rothenberg, Gayatry Mohapatra, Miguel N Rivera, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 9, 2010
Isolation of circulating tumor cells using a microvortex-generating herringbone-chipShannon L Stott, Chia-Hsien Hsu, Dina I Tsukrov, et al.
Nature Medicine|April 26, 2011
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapyJoachim Lupberger, Mirjam B Zeisel, Fei Xiao, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2007
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profilingUltan McDermott, Sreenath V Sharma, Lori Dowell, et al.
Cancer Discovery|June 3, 2023
SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted TherapyAlexander Drilon, Manish R Sharma, Melissa L Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2020
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with CrizotinibEzra Y Rosen, Melissa L Johnson, Sarah E Clifford, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 29, 2020
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven MalignanciesBenjamin J Solomon, Lavinia Tan, Jessica J Lin, et al.
Cancer Discovery|May 1, 2024
A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose EscalationRona Yaeger, Meredith A McKean, Rizwan Haq, et al.
Cancer Discovery|June 5, 2017
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid TumorsAlexander Drilon, Ramamoorthy Nagasubramanian, James F Blake, et al.
Pageof 4